Efficacy and tolerability of an endogenous metabolic modulator (AXA1125) in fatigue-predominant long COVID: a single-centre, double-blind, randomised controlled phase 2a pilot study

Lucy Finnigan, Mark Philip Cassar, Margaret James Koziel, Joël Pradines, Hanan Lamlum, Karim Azer, Dan Kirby, Hugh Montgomery, Stefan Neubauer, Ladislav Valkovič, Betty Raman

EClinicalMedicine · 2023

Read source ↗ All evidence

Summary

Axcella Therapeutics.

Source type: Peer-reviewed study
DOI: 10.1016/j.eclinm.2023.101946
Catalogue ID: BFmoakvpzf-37bi4f

Pulse AI · ask about this record

Dig deeper with Pulse AI.

Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.

How does this finding apply in a UK context?→What are the most cited records on this topic?→